Press release
Psoriasis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Psoriasis Overview
Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2%of the world population. It can be observed in the form of recurring red and scaly skin plaques that can be prominently differentiated from the normal adjacent skin.
"Psoriasis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market.
The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Psoriasis Pipeline Report: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Psoriasis treatment therapies with a considerable amount of success over the years. Psoriasis Key players such as - Luye pharma group, Cantagria, Azora Therapeutics, Boston Pharmaceuticals, Eli Lilly and Company, Escalier Biosciences, DelArrivo, Inc., Aldeyra Therapeutics, Aurigene Discovery Technologies, AbbVie, Amgen, Akeso Biopharma, CanFite Biopharma, and others, are developing therapies for the Psoriasis treatment
• Psoriasis Emerging therapies such as - TS1808, CAN 10, AT193, BOS-475, LY3361237, ESR114, DLX105-DMP, ADX-629, AUR-101, Cedirogant, ABP 654, AK-101, Piclidenoson, and others are expected to have a significant impact on the Psoriasis market in the coming years.
• Bristol Myers Squibb initiated an Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis. The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study
Psoriasis Pipeline Therapeutics Assessment
• Psoriasis Assessment by Product Type
• Psoriasis By Stage and Product Type
• Psoriasis Assessment by Route of Administration
• Psoriasis By Stage and Route of Administration
• Psoriasis Assessment by Molecule Type
• Psoriasis by Stage and Molecule Type
DelveInsight's Psoriasis Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Psoriasis Drugs Under Different Phases of Clinical Development Include:
• TS1808: Luye pharma group
• CAN 10: Cantagria
• AT193: Azora Therapeutics
• BOS-475: Boston Pharmaceuticals
• LY3361237: Eli Lilly and Company
• ESR114: Escalier Biosciences
• DLX105-DMP: DelArrivo, Inc.
• ADX-629: Aldeyra Therapeutics
• AUR-101: Aurigene Discovery Technologies
• Cedirogant: AbbVie
• ABP 654: Amgen
• AK-101: Akeso Biopharma
• Piclidenoson: CanFite Biopharma
Get a Free Sample PDF Report to know more about Psoriasis Pipeline Assessment- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Psoriasis Pipeline Analysis:
The Psoriasis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Psoriasis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
• Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Psoriasis product details are provided in the report. Download the Psoriasis pipeline report to learn more about the emerging Psoriasis therapies
https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Psoriasis Pipeline Market Drivers
• Rapidly increasing geriatric population, growing prevalence
• The Huge Pipeline of Biosimilar and biologics
• Favourable reimbursement policies
Psoriasis Pipeline Market Barriers
• High cost of treatment
• Side effects associated with existing medication
Scope of Psoriasis Pipeline Drug Insight
• Coverage: Global
• Key Psoriasis Companies: Luye pharma group, Cantagria, Azora Therapeutics, Boston Pharmaceuticals, Eli Lilly and Company, Escalier Biosciences, DelArrivo, Inc., Aldeyra Therapeutics, Aurigene Discovery Technologies, AbbVie, Amgen, Akeso Biopharma, CanFite Biopharma, and others
• Key Psoriasis Therapies: TS1808, CAN 10, AT193, BOS-475, LY3361237, ESR114, DLX105-DMP, ADX-629, AUR-101, Cedirogant, ABP 654, AK-101, Piclidenoson, and others
• Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
• Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers
Request for Sample PDF Report for Psoriasis Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Psoriasis Report Introduction
2 Psoriasis Executive Summary
3 Psoriasis Overview
4 Psoriasis- Analytical Perspective In-depth Commercial Assessment
5 Psoriasis Pipeline Therapeutics
6 Psoriasis Late Stage Products (Phase II/III)
7 Psoriasis Mid Stage Products (Phase II)
8 Psoriasis Early Stage Products (Phase I)
9 Psoriasis Preclinical Stage Products
10 Psoriasis Therapeutics Assessment
11 Psoriasis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Psoriasis Key Companies
14 Psoriasis Key Products
15 Psoriasis Unmet Needs
16 Psoriasis Market Drivers and Barriers
17 Psoriasis Future Perspectives and Conclusion
18 Psoriasis Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Psoriasis drugs and therapies- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Psoriasis Market https://www.delveinsight.com/report-store/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Psoriasis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Psoriasis Epidemiology https://www.delveinsight.com/report-store/psoriasis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Psoriasis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2863522 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
